Blockchain Registration Transaction Record

Sigyn Therapeutics Unveils CardioDialysis to Combat Heart Disease

Sigyn Therapeutics introduces CardioDialysis™ to treat cardiovascular disease in dialysis patients. The device targets multiple inflammatory pathways and could reduce major cardiac events by leveraging existing dialysis infrastructure.

This development matters because cardiovascular disease remains the world's leading cause of death, and current pharmaceutical treatments have significant limitations, particularly for vulnerable populations like dialysis patients who face mortality rates exceeding 67% from heart-related complications. The CardioDialysis approach represents a paradigm shift in cardiovascular care by leveraging existing dialysis infrastructure to deliver broad-spectrum treatment that could substantially reduce major adverse cardiovascular events. For the millions of people at risk of cardiovascular disease and the 550,000 Americans receiving regular dialysis treatments, this technology offers hope for extended life expectancy and improved quality of life. The potential to transform dialysis clinics into comprehensive treatment centers could revolutionize how we manage cardiovascular health in high-risk populations while creating substantial economic value for healthcare providers and patients alike.